CCM
BNTX icon

CAAS Capital Management’s BioNTech BNTX Stock Holding History

CAAS Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,800
Closed -$418K – 851
2022
Q2 		$418K Buy
+2,800
New +$428K 0.02% 563

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

CAAS Capital Management's BNTX Position: Q1 2025 in Review

CAAS Capital Management held its BioNTech (BNTX) position steady in Q1 2025 at 17,190 shares worth $1.57M. The position accounts for 0.17% of the portfolio, ranked #136.

CAAS Capital Management first reported a position in BNTX in Q1 2021 and has held it in 10 quarters since. The position peaked at $2.04M in Q3 2024. 280 funds tracked by Wall St. Rank hold BNTX as of Q1 2025.

  • CAAS Capital Management held 17,190 shares of BioNTech worth $1.57M as of Q1 2025.
  • CAAS Capital Management left its BioNTech share count unchanged in Q1 2025.
  • BioNTech made up 0.17% of CAAS Capital Management's portfolio in Q1 2025, its #136 holding.
  • CAAS Capital Management first reported a position in BioNTech in Q1 2021 and has held it in 10 quarters since.
  • CAAS Capital Management's BioNTech position peaked at $2.04M in Q3 2024.
  • 280 funds tracked by Wall St. Rank held BioNTech as of Q1 2025.

Based on CAAS Capital Management's 13F filing for Q1 2025, filed 1 May 2025.